Business & Consumer Services » Shell companies | Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
481.20
258.10
129.40
199.90
1,305.70
4,273
Total Accounts Receivable
-
-
200.00
-
-
-
Other Current Assets
76.90
281.20
268.60
233.50
62.30
61.40
Total Current Assets
558.00
539.30
598.00
433.40
1,368.10
4,334.40
Total Assets
558.00
539.30
598.00
433.40
1,368.10
4,336.70
Accounts Payable
107.80
-
-
-
312.00
Other Current Liabilities
214.00
273.40
285.60
218.70
61.00
Total Current Liabilities
321.80
273.40
285.60
218.70
373.00
Total Liabilities
321.80
273.40
285.60
218.70
373.00
Common Equity (Total)
236.30
265.90
1,437.70
3,285.20
2,505.00
Total Shareholders' Equity
236.30
265.90
312.30
214.80
995.00
Total Equity
236.30
265.90
312.30
214.80
995.00
Liabilities & Shareholders' Equity
558.00
539.30
598.00
433.40
1,368.10
Preferred Stock (Carrying Value)
-
-
1,750.00
3,500.00
3,500.00

About Lixte Biotechnology Holdings

View Profile
Address
248 Route 25A No. 2
East Setauket New York 11733
United States
Employees -
Website http://www.lixte.com
Updated 07/08/2019
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. It uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The company was founded by John S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.